MRSH — Marsh & McLennan Companies, Inc.

Consensus is a genuine 'Hold' - roughly 10 buy/strong-buy ratings against 22 holds and 1 sell - with a $202.71 average target and a wide $180-$234 range. The tape is mixed: the stock popped ~4% on 2026-10-15 after the Q3 beat, but it is still -1.13% over the prior month and only +1.24% over three months. October 2026 saw targets cut at Morgan Stanley ($180) and Keefe Bruyette ($186) on slowing organic growth, offset by bullish revisions at JPMorgan ($215) and UBS ($222). The overhang is concrete: $144M of Greensill litigation cost in Q3 alone and $569M year-to-date, plus reinsurance weakness (Guy Carpenter revenue -6%).

Revenue growth is decelerating but still solid: YoY comparisons went from +9.1%/+12.1%/+11.5% across Q1-Q3 2025 to +7.6%/+6.2%/+8.1% across Q1-Q3 2026, with underlying organic growth of roughly 5% versus sector peaks near 7%. The real deterioration is in profit conversion. Operating margin fell YoY in all three 2026 quarters - Q1 23.1% vs 28.4%, Q2 25.6% vs 26.2%, Q3 17.7% vs 18.4% - so operating income grew ~4% against ~8% revenue. This is a multi-quarter trend, not a blip: the same quarters in 2024 printed 29.7%, 26.4% and 19.4%, meaning margins have now compressed three quarters running against two consecutive prior-year comparables. Free cash flow confirms it: TTM FCF through 2026-09-30 is $4.15B versus $4.83B a year earlier (-14%), dragged by -$750M of Q1 seasonality plus litigation cash outflows. Q3 GAAP EPS of $1.69 (+11.9% YoY) actually flatters a quarter that absorbed the $144M Greensill charge; adjusted EPS was $2.03. Verdict: top line steady-to-slowing, margins and cash conversion eroding - decelerating profit quality, not yet a revenue inflection.

As of 2026-10-15, at $185.51 MRSH traded at 22.1x TTM GAAP EPS of $8.489, 5.92x book, 3.11x sales and 19.1x EV/EBITDA, versus a five-year average TTM P/E of 25.53x and average P/S of 4.03x - roughly 13% below its own earnings multiple and ~23% below its own sales multiple. That is modestly cheap versus its own history and roughly fair versus broker peers. On the forward number the discount widens: 17.8x consensus next-FY EPS of $10.446 against ~10-11% expected EPS growth, i.e. an ~1.7x PEG - not distressed, but not demanding. Note the feed's PEG ratio of -9.96e14 is a data artifact, not a signal. The discount is partly earned: organic growth has cooled from ~7% to ~4-5%, margins are compressing, and TTM FCF is down 14%, so this is a modest re-rating candidate rather than a deep-value setup.

The market is paying 17.8x forward consensus EPS while applying only 22.1x to depressed trailing GAAP EPS - in other words it is already looking through the Greensill charge and pricing roughly 10% earnings recovery, not a structural break. The tell is the GAAP-versus-adjusted gap: $1.69 reported vs $2.03 adjusted in Q3 2026, a $0.34/share (~$160M) delta. If that gap closes as litigation rolls off and margins stabilize, the multiple has room to drift back toward the 22-24x range; if organic growth keeps sliding toward 3-4% and YoY margin compression continues, 17-18x is where the stock stays. Watch the quarterly organic growth print and the YoY operating-margin delta - those two lines, not the EPS headline, decide whether the discount closes.

As of 2026-10-15, RSI(14) stood at 56.23 - neutral, neither overbought nor oversold. The $185.51 price was +3.24% above its 20-day SMA (the earnings-day pop), -1.69% below its 50-day SMA, and +0.96% above its 200-day SMA: a broad range with a fresh short-term up-move that has not yet reclaimed the 50-day. The 52-week range is $156.60-$198.49, leaving the stock ~6.5% below its high and ~18% above its low. Trailing returns (+2.73% 1wk, -1.13% 1mo, +1.24% 3mo, +2.0% 6mo) describe six months of sideways chop, not a trend, and beta of 0.585 means moves will be slow. Entry implication: this is not an oversold entry. A decisive close above the ~$190-192 area would confirm buyers are paying up for the beat; a fade back below the 20-day keeps the $175-195 range intact.

• Softening P&C and reinsurance pricing: sector organic growth has decelerated from ~7% to ~4-5% in 2026, and Guy Carpenter revenue fell 6% in Q3 2026 as reinsurance pricing turned.
• Interest rates and fiduciary float: elevated rates boosted investment income on client cash, but a moderating rate trajectory plus rising legal/restructuring cash outflows is tightening reported operating cash flow.
• Legal and litigation cost inflation: the multi-quarter Greensill matter ($569M year-to-date) plus general professional-services litigation exposure is now a recurring drag on GAAP earnings and cash.
• Broker-sector consolidation and integration risk: Marsh's own McGriff and Accel Holdings deals plus a consolidating peer set (Aon, Gallagher) keep integration and synergy execution in focus.
• Professional-services labor costs and client budgets: wage inflation and corporate cost discipline pressure Mercer/Oliver Wyman consulting margins even as that segment outperformed with 14% growth.

• Q4 2026 / FY2026 results on 2027-01-26 (estimated) - the first clean read on whether organic growth and YoY operating margins stabilize.
• Thrive efficiency program: any quantified cost-savings targets or realized margin benefit would directly address the biggest bear point.
• McGriff and Accel Holdings integration milestones and cost-synergy realization, alongside the completed corporate brand transition to 'Marsh'.
• January reinsurance renewal season - the read-through for Guy Carpenter, which is the weakest segment right now.
• Resolution or clear quantification of remaining Greensill litigation exposure, which would close the GAAP-versus-adjusted EPS gap.
• Continued capital return - $500M of buybacks (2.7M shares) in Q3 2026 - plus the next dividend increase.

• Organic growth slipping below 4% as property, casualty and reinsurance pricing soften; Q3 revenue growth of 8.1% was flattered by acquisitions, with underlying growth only ~5%.
• Sustained margin compression - YoY operating margin fell in all three 2026 quarters (Q1 23.1% vs 28.4%, Q2 25.6% vs 26.2%, Q3 17.7% vs 18.4%) despite mid-single-digit revenue growth.
• Rising financial leverage: long-term debt has climbed from $11.84B at 2023-12-31 to $20.36B at 2026-09-30 against equity of just $14.91B (reported debt/equity 1.50x), largely deal- and buyback-funded.
• Litigation: $569M of Greensill costs year-to-date and not fully resolved - further charges would keep GAAP earnings and cash flow below the adjusted narrative.
• Cash-flow strain: TTM FCF of $4.15B (-14% YoY) against roughly $1.95B of annual dividends plus active buybacks, with only $1.84B of cash versus $22.1B of current liabilities (current ratio 1.09).
• Multiple compression if the broker sector de-rates further on slower organic growth - MRSH's 5-year average P/E of 25.53x is unlikely to be recaptured in a 4-5% growth world.

Marsh is a genuinely high-quality, low-beta (0.585) fee-based intermediary - 27.5% ROE, 12.1% ROIC, 14.2% net margin, a 2.2% dividend and $4B+ of annual FCF - and at 17.8x consensus next-FY EPS it trades at a real discount (roughly 13%) to its own five-year average P/E of 25.53x. But the reported numbers are genuinely deteriorating at the margin: three straight quarters of YoY operating-margin compression, revenue growth slowing from 9-12% in 2025 to 6-8% in 2026, TTM free cash flow down 14%, and long-term debt nearly doubling since end-2023 to $20.36B. That combination - a cheap-versus-history multiple attached to weakening near-term fundamentals - is the definition of unclear, which is why the lean stays cautious rather than constructive. I would want to see organic growth hold near 5% and YoY margins stop falling before treating the discount as a value opportunity rather than a value trap.

I applied a justified 20x forward P/E - a discount to MRSH's own 5-year average of 25.5x and its 22.1x TTM multiple, reflecting ~5% organic growth and ongoing margin compression, but a premium to the market for a wide-moat, 0.585-beta broker - to consensus next-FY EPS of $10.446, giving ~$209. Cross-checking with normalized free cash flow (TTM $4.15B plus roughly $0.45B of one-off Greensill cash drag, capitalized at a 4.75% FCF yield) yields ~$203 on 477M shares, so I blended the two to $206, about 11% above the 2026-10-15 close of $185.51.